Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
' The Food and Drug Administration approved new label information in late August for the nonnucleoside analog Sustiva. It indicates a Sustiva-based regimen is effective in suppressing HIV replication for at least three years. ' The FDA gave marketing approval in September for the spermicidal lubricant Amphora. Early clinical trials show the product helps prevent HIV, gonorrhea, herpes, and chlamydia infections. ' The FDA gave priority review status in October to Roche's application to market a combination of its hepatitis C treatments Pegasys and Copegus to patients coinfected with HIV and HCV. A decision is expected by February. ' Bristol-Myers Squibb has submitted a new-drug application to the FDA for its hepatitis B treatment entecavir. The antiviral has been shown to block three steps in HBV replication. An FDA decision may come by the spring. ' A study in the August 1 issue of Clinical Infectious Diseases has shown that once-daily dosing of Epivir is as effective as twice-daily dosing when given as part of a drug regimen also containing AZT and Sustiva. ' A study by researchers at the University of New Mexico has shown that blood-based levels of the protease inhibitor Fortovase, when boosted once daily with low doses of Norvir, are significantly higher in women than in men because of sex-related pharmacokinetic differences. ' Blood-based levels of the protease inhibitor Viracept are about 34% lower in pregnant HIV-positive women than in other HIV-positive females, researchers reported in the September 1 issue of Clinical Infectious Diseases. ' Study data presented at the 42nd Infectious Disease Society of America meeting have shown that heavily treated HIV patients who add fusion inhibitor Fuzeon to a drug regimen containing an active protease inhibitor are twice as likely to have a significant virologic response than those on a protease inhibitor'based regimen alone. ' Gilead Sciences reported in August that midterm data from a 48-week clinical trial have shown that a Sustiva-based regimen also containing its anti-HIV drugs Viread and Emtriva suppressed HIV levels to fewer than 400 copies in 88% of study participants, compared to 80% of those on a Sustiva-Combivir regimen. ' A study in the August edition of the European Journal of Clinical Investigation has shown that switching from a protease inhibitor to nonnucleoside analog Viramune significantly lowers triglycerides and boosts HDL, or 'good,' cholesterol levels after 24 weeks of treatment. ' A 96-week study of Fuzeon has shown that the fusion inhibitor was safe and generally well-tolerated by HIVpositive children ages 4 to 14. ' A study in the June 18 issue of the journal AIDS has shown that treatment with the nucleoside analog Videx EC and hydroxyurea produced higher HIV-specific CD8- and CD4-cell responses than a standard three-drug antiretroviral regimen. ' A study in the August 1 issue of Journal of Acquired Immune Deficiency Syndromes has shown that elevated lactate levels associated with the nucleoside analog Zerit improve after switching to another nucleoside drug. ' Researchers reported in July that coadministration of Videx EC and Viread raises the risk for pancreatitis. ' Researchers reported in the September 3 issue of the journal AIDS that HIV-HCV coinfected patients treated with PegIntron and Rebetol were more likely to have undetectable hepatitis C levels after six months than those treated with Intron A and Rebetol. ' Roche and Trimeris have launched Accelerated Simultaneous Access Program for the fusion inhibitor Fuzeon, through which patients taking an experimental anti-HIV drug are given up to a 60-day supply of the medication. ' The antifungal Micafungin is useful in treating HIV-related esophageal candidiasis, according to a study in the September 15 issue of Clinical Infectious Diseases. The drug was submitted in April for FDA approval for this use. ' A Thai study of the experimental therapeutic HIV vaccine Remune has shown that injections of the vaccine every 12 weeks for 132 weeks slowed HIV disease progression in 223 HIV-positive study subjects. ' Anormed halted development in October of its CXCR4 receptor inhibitor AMD3100 after a study showed only one of 40 test subjects had a significantly reduced viral level. ' Argos Therapeutics has announced upcoming human safety tests of an individualized HIV vaccine that uses the viral genes taken from an HIV-positive person to prompt an individualized immune system response. ' The October 14 edition of Science reported that researchers have developed an experimental HIV microbicide that blocks the CCR5 receptor, which HIV uses to infect human cells. The gel prevented vaginal HIV infections in monkeys. ' GlaxoSmithKline reached an agreement with the International Partnership for Microbicides in September to test its anti-HIV drugs for potential use in HIV microbicide gels.
From our Sponsors
Most Popular
Lexi Love comes out as HIV+ after Trump deletes federal resources
January 23 2025 11:23 AM
Grindr is reminding us why jockstraps are so sexy and iconic
May 02 2025 5:36 PM
BREAKING NEWS: Trump admin moves to end federal HIV prevention programs
March 18 2025 6:10 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Tyler TerMeer vows to continue to fight for health care for all
January 28 2025 3:00 PM
Discover the power of Wellness in your life
March 26 2025 12:41 PM
Plus: Featured Video
Latest Stories
Dancer. Healer. Survivor. DéShaun Armbrister is all of the above
July 02 2025 8:23 PM
Two right-wing Supreme Court justices signal they may uphold access to PrEP and more
April 21 2025 4:10 PM
Broadway's best raise over $1 million for LGBTQ+ and HIV causes
April 03 2025 7:15 PM
Plus nominated for 2025 GLAAD Media Award
January 22 2025 12:42 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
BREAKING: Supreme Court rules to save free access to preventive care, including PrEP
June 27 2025 10:32 AM
1985: the year the AIDS crisis finally broke through the silence
June 26 2025 11:24 AM
Trump admin guts $258 million in funding for HIV vaccine research
June 03 2025 3:47 PM
500,000 Children at Risk: PEPFAR Funding Crisis
April 08 2025 3:51 PM
The Talk Season 5 premieres this spring with HIV guidance for the newly diagnosed
March 26 2025 1:00 PM
Jess King is here to help you live your happiest, healthiest life yet
March 24 2025 4:35 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
VIDEO: A man living with HIV discusses his journey to fatherhood
June 10 2025 4:58 PM
HRC holds 'die-in' to protest Trump health care cuts
April 28 2025 2:11 PM
Season 4 of The Switch on resilience & radical self-love returns this spring
March 26 2025 12:20 PM
Gerald Garth is keeping people of color happy and healthy through trying times
March 11 2025 3:38 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM